A large international study suggests that donor stem cell transplantation may provide a meaningful chance of long-term survival — and potentially cure — for people with hepatosplenic T-cell lymphoma, one of the rarest and most aggressive forms of blood cancer.
Researchers analyzed outcomes for 121 adults treated at 64 centers across Europe and Asia. The study, published in The Lancet Haematology, is the largest analysis to date of stem cell transplantation for this particularly difficult-to-treat lymphoma.
Donor Transplants Show Promising ResultsHepatosplenic T-cell lymphoma is an uncommon and highly aggressive cancer that affects the blood and lymphatic system. There is currently no universally accepted standard treatment, and the disease often responds poorly to chemotherapy.
Of the 121 patients included in the study, 94 underwent allogeneic hematopoietic stem cell transplantation, using stem cells donated by another person. The remaining 27 received an autologous transplant, in which their own previously collected stem cells were returned after intensive chemotherapy.
The results favored donor transplantation. Three years after an allogeneic transplant, 55% of patients were still alive, while 50.5% had remained free of relapse or disease progression.
The condition of patients at the time of transplantation also had a major impact on outcomes. Those who entered transplantation in complete remission had almost three times the likelihood of survival compared with patients who still had active disease.
Importantly, however, transplantation was not necessarily futile for people with progressive lymphoma. About one-third of patients who underwent transplantation while their disease was still active achieved long-term survival.
The researchers therefore caution against automatically excluding patients with unfavorable prognostic factors from donor transplantation.
Another important predictor was lactate dehydrogenase (LDH), a routine blood marker. Patients with normal LDH levels at diagnosis had significantly better outcomes than those with elevated levels.
Relapse was the main obstacle to long-term success. Approximately 38% of patients experienced a relapse within three years. At the same time, deaths directly associated with the transplant procedure were relatively uncommon, occurring in fewer than 12% of patients. The researchers note that the relatively young age of the study population — the median age was 36 — may have contributed to the lower treatment-related mortality.
According to the researchers, the results indicate that donor transplantation can provide a genuine, although not guaranteed, possibility of cure. A key factor may be the ability of donor immune cells to recognize and attack lymphoma cells that remain after treatment, an effect known as the graft-versus-lymphoma response.
Autologous Transplants Were Less EffectiveResults were considerably less favorable among the patients who received autologous transplantation.
This group was already considered lower risk: 74% of patients were in complete remission before transplantation. Nevertheless, only about 39% remained free of disease progression three years later, and half experienced a relapse.
The researchers suggest that the difference may be explained by the mechanism of treatment. Autologous transplantation relies primarily on high-dose chemotherapy to eliminate remaining cancer cells, whereas donor transplantation also provides an immune response against the lymphoma.
Hepatosplenic T-cell lymphoma may be sufficiently resistant to chemotherapy that this approach does not provide lasting disease control, even when patients initially respond well.
Study Provides a Clearer Treatment StrategyTreatment recommendations for hepatosplenic T-cell lymphoma have traditionally been based on small case series and limited clinical evidence. The new analysis, which is more than twice the size of previous studies, provides a stronger indication of what patients and doctors can expect from stem cell transplantation.
The authors suggest that eligible patients should receive intensive initial chemotherapy followed, whenever possible, by an early allogeneic transplant. Autologous transplantation could be considered for patients who achieve complete remission but are not candidates for a donor transplant.
The researchers acknowledge an important limitation: the study included only patients who ultimately underwent transplantation. Therefore, the findings cannot show how people who were considered for transplantation but never received it might have fared.
Because hepatosplenic T-cell lymphoma is extremely rare, assembling substantially larger study populations will remain difficult. Nevertheless, the researchers say that confirming these findings in larger cohorts will be an important next step.
Overall, the study provides encouraging evidence that donor stem cell transplantation can offer some patients with this aggressive lymphoma a realistic possibility of prolonged remission and potentially cure.
Follow NEWS.am Medicine on Facebook and Twitter